TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · major macro event coming up
EXEL

Exelixis Inc

Healthcare · Biotechnology

58.20$ +0.4% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Balance Sheet

Exelixis Inc (EXEL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 2,494 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet EXEL
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
2,977 2,942 2,804 2,773 2,960 2,948 2,837 2,678 2,824 2,844 2,594 2,494
1,443 1,318 1,292 1,477 1,550 1,468 1,397 1,181 1,402 1,443 1,209 1,251
397 263 260 198 258 217 184 164 376 482 226 281
1,103 995 963 1,002 1,189 1,111 1,031 791 989 1,059 777 839
248 237 241 397 270 265 282 292 310 287 329 335
25 17 21 21 21 22 25 23 27 22 27 29
374 – – – – – – – – – – –
64 64 64 64 64 64 64 64 64 64 64 64
629 678 676 653 685 703 706 645 663 683 658 650
377 394 373 346 394 404 399 336 374 406 371 362
7.0 26 4.1 – -3.3 25 – – – – – –
26 34 26 29 59 38 43 26 25 30 24 39
2,348 2,264 2,128 2,120 2,275 2,244 2,131 2,034 2,161 2,161 1,936 1,844
-126 -173 -259 -200 -90 -99 -163 -220 -106 -77 -216 -263
319 313 306 294 291 282 288 284 279 282 267 260

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?